Breztri Aerosphere is NOT indicated for severe asthma and should NOT be used in asthma patients
Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) is FDA-approved exclusively for COPD maintenance treatment, not for asthma of any severity. 1 The FDA label explicitly states that "the safety and efficacy of BREZTRI AEROSPHERE in patients with asthma have not been established" and that it "is not indicated for the treatment of asthma." 1
Critical Safety Concern
The use of long-acting beta2-agonists (LABA) as monotherapy without inhaled corticosteroids in asthma is associated with increased risk of asthma-related death. 1 While Breztri contains an ICS component, it has never been studied in asthma populations, making its risk-benefit profile in severe asthma completely unknown.
What the Evidence Actually Shows
You are asking about the wrong medication. The studies you may be confusing this with involve:
Beclomethasone/formoterol/glycopyrronium (BDP/FF/G, marketed as Trimbow®) - This is a DIFFERENT triple therapy that HAS been studied in asthma:
- The TriMaximize study 2 demonstrated effectiveness in moderate-to-severe asthma with improvements in ACT scores (mean change 3.9 at 12 months), FEV1 (increased 142 mL), and achievement of clinical remission in 45.6% of patients in the first year
- A 2025 network meta-analysis 3 showed BDP/FF/G significantly reduced severe exacerbations compared to other single-inhaler triple therapies in uncontrolled asthma
- Real-world data 4 showed improvements in lung function and reduced diaphragmatic workload after 3 months of BDP/FF/G treatment
Budesonide/glycopyrronium/formoterol (BGF, Breztri Aerosphere) was recently studied in the KALOS and LOGOS trials 5 specifically in asthma patients, showing:
- Improved lung function (76 mL improvement in trough FEV1 vs. budesonide-formoterol)
- Reduced severe exacerbations (14% reduction, rate ratio 0.86)
- However, these trials were conducted AFTER the current FDA labeling, and the drug remains unapproved for asthma
Current Guideline-Based Approach for Severe Asthma
For patients with severe persistent asthma, established guidelines recommend 6:
Step 4 Treatment:
- High-dose inhaled corticosteroids
- Long-acting inhaled beta2-agonists
- If needed: oral corticosteroids (lowest effective dose)
Adding a third controller medication (like a LAMA) to ICS-LABA has limited evidence in severe asthma. A 2002 study found no benefit from adding leukotriene modifiers as a third agent 6, and guidelines state that "evidence to date does not support using a third long-term-control medication added to inhaled corticosteroids and long-acting inhaled beta2-agonists in order to avoid using systemic corticosteroid therapy." 6
The Bottom Line
If you are considering triple therapy for severe asthma:
- Do NOT use Breztri Aerosphere - it is contraindicated and potentially dangerous
- Consider BDP/FF/G (Trimbow®) if available in your region, as it has demonstrated efficacy and safety in asthma populations
- Consult with an asthma specialist, as recommended for all severe persistent asthma cases 6
- The standard approach remains high-dose ICS-LABA, with oral corticosteroids added if control is not achieved